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David E. Elder10, Boris C. Bastian9, Ketty Peris1 and Maria T. Landi3
Melanocortin-1 receptor (MC1R) variants have been associated with BRAF (v-raf murine sarcoma viral oncogene
homolog B1) mutations in non-CSD (chronic solar-damaged) melanomas in an Italian and an American
population. We studied an independent Italian population of 330 subjects (165 melanoma patients and 165
controls) to verify and estimate the magnitude of this association and to explore possible effect modifiers. We
sequenced MC1R in all subjects and exon 15 of BRAF in 92/165 melanoma patients. Patients with MC1R variants
had a high risk of carrying BRAF mutations in melanomas (odds ratio (OR)¼ 7.0, 95% confidence interval
(CI)¼ 2.1–23.8) that increased with the number of MC1R variants and variants associated with red hair color.
Combining these subjects with the originally reported Italian population (513 subjects overall), MC1R variant
carriers had a 5- to 15-fold increased risk of BRAF-mutant melanomas based on carrying one or two variants
(Po0.0001, test for trend), and regardless of signs of chronic solar damage. In contrast, no association with
BRAF-negative melanomas was found (OR¼ 1.0, 95% CI¼ 0.6–1.6). No characteristics of subjects or melanomas,
including age, nevus count, pigmentation, and melanoma thickness or location on chronically or intermittently
sun-exposed body sites, substantially modified this association, although results could be affected by the small
numbers in some categories. This study confirms that the known MC1R–melanoma risk association is confined
to subjects whose melanomas harbor BRAF mutations.
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INTRODUCTION
The melanocortin-1 receptor (MC1R) gene (MIM 155555) is a
key determinant of human pigmentation, and is highly
polymorphic in Caucasians with specific variants linked to
the red hair color phenotype (Rees, 2004; Gerstenblith et al.,
2007). As shown in many studies worldwide, MC1R is also a
low-penetrance melanoma susceptibility gene (Valverde
et al., 1996; Palmer et al., 2000; Kennedy et al., 2001;
Dwyer et al., 2004; Matichard et al., 2004; Landi et al., 2005;
Kanetsky et al., 2006; Stratigos et al., 2006; Fargnoli et al.,
2006a; Fernandez et al., 2007).
The BRAF oncogene (MIM 164757) encodes a serine/
threonine kinase that acts in the Ras–RAF–MAPK (mitogen-
activated protein kinase) pathway, and is mutated in over
60% of cutaneous melanomas, mostly in codon 600 of exon
15 (Davies et al., 2002). A higher frequency of BRAF
mutations was found in melanomas occurring on skin with
absent or minor histopathological signs of chronic solar
damage (CSD) (‘‘non-CSD melanomas’’) as compared to
‘‘CSD melanomas’’ (Maldonado et al., 2003).
Variants of MC1R have been recently reported to be
associated with BRAF mutation status in non-CSD melano-
mas in an Italian and an American population (Landi et al.,
2006). A few hypotheses were suggested to explain the
underlying mechanism responsible for this association, but
no analysis could be performed because of the small sample
size and/or lack of data on phenotypic characteristics of the
American study subjects.
We studied an independent Italian population from central
Italy to (i) verify the association of MC1R variants and BRAF-
mutant melanomas; (ii) explore possible effect modifiers of
the association combining data of this population with data
from the originally reported Italian population in Landi et al.
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(2006); and (iii) estimate the magnitude of the MC1R–BRAF
association in comparison with the overall risk of melanoma
associated with carrying MC1R variants, taking advantage of
the MC1R data on control subjects from both Italian
populations.
RESULTS AND DISCUSSION
We defined our study population as ‘‘population 1,’’ and the
original Italian population in Landi et al. (2006) as ‘‘popula-
tion 2,’’ Identified MC1R variants in both populations are
listed in Table S1.
In population 1, melanoma patients with at least one
germline MC1R variant had a sevenfold (95% CI¼ 2.1–23.8)
increased risk of developing melanomas with BRAF muta-
tions as compared with the individuals with two wild-type
alleles (P¼ 0.002) (Table 1). Categorization in three finer
groups showed that odds of BRAF-mutant melanomas
increased progressively with the number of MC1R variants
(P-trendo0.01) (Table 1). Additional inclusion of D84E
among the ‘‘R’’ variants (Duffy et al., 2004) did not
significantly modify the association (data not shown). For
comparison, results from the Italian population in Landi et al.
(2006), not stratified by CSD (defined as population 2), are
reported in Table 1. Overall, the MC1R–BRAF association
was similar in both Italian populations. Interestingly, in
population 1, the association was stronger for multiple MC1R
variants than for other MC1R classifications based on variant
type (‘‘R’’ or ‘‘r’’), whereas in population 2, ‘‘R’’ variants
played a major role (Table 1), possibly reflecting small
numbers in some categories and different frequency of
variants (Table S1).
Characteristics of patients and melanomas did not
significantly differ between the two Italian populations
(Table S2), with the exception of nevus count that followed
different assessment and scoring criteria (population 1,
X2mm nevi counted on the entire body and population 2,
nevi of any size counted on the back only). BRAF mutations
were present in 43.5% of melanomas in population 1 and
63.5% in population 2 (P¼0.01) and were not affected by
anatomical location of the primary melanoma. In popula-
tion 1, mutations were more frequent in thicker melanomas,
whereas they were evenly distributed among in situ
melanomas (Table S3).
Table 1. Association between germline variants of MC1R and somatic BRAF mutations in melanoma patients from
two Italian populations
Population 1 Population 21 Combined
MC1R
genotype2
BRAF
wt
BRAF
mutant
OR
(95% CI)3 P-value
BRAF
wt
BRAF
mutant
OR
(95% CI)3 P-value
BRAF
wt
BRAF
mutant
OR
(95% CI)3 P-value
wt/wt 20 4 Reference 9 3 Reference 29 7 Reference
Any variant 32 36 7.0 (2.1–23.8) 0.002 22 51 8.4 (1.9–36.9) 0.005 54 87 7.3 (2.9–18.5) o0.0001
wt/wt 20 4 Reference 9 3 Reference 29 7 Reference
r/wt or R/wt 24 21 5.6 (1.6–20.2) 0.008 17 33 7.4 (1.6–33.4) 0.01 41 54 6.0 (2.3–15.9) 0.0003
r/r or R/r or R/R 8 15 10.3 (2.5–42.1) 0.001 5 18 11.3 (2.1–62.1) 0.005 13 33 10.5 (3.6–31.0) o0.0001
Total 52 40 P-trend 0.001 31 54 P-trend 0.008 83 94 P-trend o0.0001
wt/wt 20 4 Reference 9 3 Reference 29 7 Reference
r/wt 14 14 6.5 (1.7–25.3) 0.007 13 21 6.0 (1.3.28.2) 0.02 27 35 5.8 (2.1–16.1) 0.0007
r/r or R/r or R/wt
or R/R
18 22 7.4 (2.0–26.9) 0.002 9 30 11.9 (2.4–57.6) 0.002 27 52 8.6 (3.2–23.2) o0.0001
Total 52 40 P-trend 0.004 31 54 P-trend 0.003 83 94 P-trend o0.0001
wt/wt 20 4 Reference 9 3 Reference 29 7 Reference
r/wt or r/r 17 19 6.9 (1.9–25.7) 0.004 15 26 6.3 (1.4–29.0) 0.02 32 45 6.3 (2.3–16.8) 0.0003
R/wt or R/r or R/R 15 17 7.1 (1.9–26.9) 0.004 7 25 13.0 (2.5–67.0) 0.002 22 42 8.7 (3.1–24.1) o0.0001
Total 52 40 P-trend 0.006 31 54 P-trend 0.003 83 94 P-trend o0.0001
BRAF, v-raf murine sarcoma viral oncogene homolog B1; CSD, chronic solar-damaged; CI, confidence interval; MCIR, melanocortin-1 receptor; OR, odds
ratio; wt, wild type.
1Data from Landi et al. (2006) combining cases with positive and negative signs of chronic solar damage in skin adjacent to the melanomas (non-CSD
melanomas+CSD-melanomas).
2MC1R variants were grouped as ‘‘R’’ (R151C, R160W, and D294H) or ‘‘r’’ variants (any non-R variant excluding synonymous changes) (Landi et al., 2005,
2006).
3Logistic regression models adjusted by median age (and by age and population in combined analyses).
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Given the similarities between the two Italian populations,
we combined them to increase the sample size and related
statistical power to investigate possible effect modifiers of
this association. In the 177 overall cases with BRAF data, we
confirmed the MC1R–BRAF association (OR¼ 7.3, 95%
CI¼2.9–18.5), with increasing risk in subjects with multiple
MC1R variants (P-trendo0.0001) (Table 1). Notably, the
MC1R–BRAF association was not significantly affected by
age, tanning ability, melanoma thickness, anatomical loca-
tion of the primary tumor, or nevus count (Table 2), although
differences in the estimates by tanning ability and melanoma
location were observed, and significance could have been
affected by the small number of subjects. We could not
perform a formal statistical analysis of the MC1R–BRAF
association in models stratified by hair or eye color (dark/
light), as some categories in these analyses included
no subjects. However, the distribution of subjects was
similar within groups, suggesting no substantial differences
in the MC1R–BRAF association by these pigmentation
characteristics.
We then proceed with a case–control analysis to estimate
the magnitude of the MC1R–BRAF association in comparison
with the overall association between MC1R variant and
melanoma risk, taking advantage of the MC1R data on all
control subjects. In population 1, we found a strong
association betweenMC1R variants and melanoma harboring
BRAFmutations (Table S4). This association was confirmed in
the combined cases and controls (n¼ 513) (Table 3). As
found in previous studies (Palmer et al., 2000; Kennedy et al.,
2001; Dwyer et al., 2004; Matichard et al., 2004; Landi et al.,
2005; Kanetsky et al., 2006; Stratigos et al., 2006; Fargnoli
et al., 2006a; Fernandez et al., 2007), the risk of melanoma
increased in subjects with MC1R variants (OR¼2.2, 95%
CI¼1.4–3.4) and, particularly, in those with multiple variants
(P-trendp0.0001). However, when we stratified the melano-
ma cases between those with melanomas harboring BRAF
mutations and those with no BRAF mutations, the risk
associated with MC1R variants was confined only to BRAF-
mutant melanomas, ranging from 5- to 15-fold in carriers of
one or multiple MC1R variants. No association was found
with melanomas without BRAF mutations (Table 3).
This confirms that in the Italian population,MC1R variants
are strongly associated with BRAF-mutant melanomas in-
dependently of the degree of solar damage in the areas
adjacent to the melanoma lesions. In the original study, the
association of MC1R with BRAF mutations was restricted to
non-CSD-melanomas in the American population, whereas
the number of CSD melanomas in the Italian population was
too small to carry out any analysis (Landi et al., 2006). The
difference between the Italian and American populations
with regard to CSD could be due to the age difference. In fact,
both Italian populations were approximately 10 years young-
er than the American population in Landi et al. (2006), and
the degree of chronic solar damage increases with age. Also,
differences in sun sensitivity between populations, and the
variations in tissue fixation and staining that could affect the
recognition of signs of CSD adjacent to the melanoma
lesions, could have played a role.
In conclusion, the original observation of an association
betweenMC1R variants and BRAF-mutant melanomas (Landi
et al., 2006) is strongly confirmed in this independent
population, whereas no association was observed in subjects
whose melanomas had no BRAF mutations. Moreover, given
the similarities between our population and the original
Italian group in Landi et al. (2006), we could pool the data of
two studies, and explore the effect of phenotypic character-
istics of subjects and the features of the melanoma lesions on
this association. No hypothesized factors modified this
association. Whether the MC1R–BRAF link is a consequence
of a direct effect of impaired MC1R on BRAF or is an
epiphenomenon of alterations in other pathways is unclear
and warrants further research.
MATERIALS AND METHODS
Study population
We analyzed 165 sporadic melanoma patients and 165 sex- and
age-matched healthy controls (82 males and 83 females, aged
17–82 years) enrolled in central Italy (L’Aquila, Florence and
Modena), from 2000 to 2002 (defined as population 1). To
increase the sample size and related statistical power of possible
effect modifiers of the MC1R–BRAF association, the results of
population 1 were compared and combined with data of the Italian
population in Landi et al. (2006) (defined as population 2), which
included 183 melanoma patients (87 males and 96 females, aged
17–77 years) and 179 control subjects (89 males and 90 females),
frequency-matched to cases in terms of sex and age by decade,
enrolled in Northeastern Italy (Bufalini Hospital of Cesena, Italy)
from 1994 to 1999. For both populations, data on characteristics of
subjects were collected through standardized questionnaires
(lifetime residential history, medical history, family history of
cancer and other diseases, UV exposure habits, skin reaction to the
first 30minutes of sun exposure, tanning ability after prolonged
sun exposure) and skin examination (skin type, hair and eye color,
freckling, number of melanocytic nevi, and presence of clinically
atypical nevi) are described in detail in Fargnoli et al. (2006b) for
population 1 and Landi et al. (2001, 2006) for population 2,
respectively. CSD in skin adjacent to melanomas was indepen-
dently assessed in melanoma tissue sections by two pathologists
(BCB and DEE), using a multipoint scale from 0 to 3þ , as
described (Landi et al., 2006). However, an unambiguous scoring
in the critical moderate-to-severe range of solar elastosis could not
be reached because of the variability and/or poor staining quality
of some hematoxylin and eosin-stained sections. As the unequi-
vocal CSD-positive cases were few as in the original Italian
population (Landi et al., 2006), we analyzed all melanomas
regardless of the CSD status.
Written informed consent was obtained under Bufalini Hospi-
tal’s, University of L’Aquila’s, and National Cancer Institute’
Institutional Review Board-approved protocols in accordance with
the Declaration of Helsinki Principles.
MC1R and BRAF sequencing
The 951bp MC1R coding region (AF153431) was directly
sequenced either in its entirety or in two overlapping fragments by
PCR followed by direct sequencing of the amplicon(s) in blood
genomic DNA from all subjects. Specific primers and sequencing
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chemistries have been previously described (Landi et al., 2005;
Fargnoli et al., 2006a).
Molecular analysis of BRAF exon 15 was carried out on somatic
DNA, extracted by manual microdissection using a dissection
microscope to select areas in which melanoma cells dominated
over stromal cells. As in the original Italian population (Landi et al.,
2006), we excluded acral melanomas because BRAF mutations are
known to be rare in these lesions (Maldonado et al., 2003). Given
the small size of the melanoma lesions and the necessity to use most
of the lesion for diagnosis, sufficient/good quality DNA for BRAF
Table 2. Association between MC1R variants and BRAF mutations stratified by age, tanning ability, melanoma
characteristics, and nevus count in the melanoma patients of the Italian populations
Population 1 N=92 Population 2 N=85 Combined N=177
Variable Values1
MC1R
genotype
BRAF
wt
BRAF
mutant
OR2
(95% CI)
BRAF
wt
BRAF
mutant OR2 (95% CI)
BRAF
wt
BRAF
mutant
OR2
(95% CI)
P-
value3
Age (below/
above median)
Below
wt/wt 9 2 Reference 5 2 Reference 13 4 Reference
0.88
Any variant 16 19 6.2 (1.1–34.2) 8 30 9.4 (1.5–57.6) 22 49 7.2 (2.1–24.7)
Above
wt/wt 11 2 Reference 4 1 Reference 16 3 Reference
Any variant 16 17 9.7 (1.5–64.6) 14 21 6.0 (0.6–59.4) 32 38 6.3 (1.7–23.7)
Tanning ability
Low
wt/wt 14 3 Reference 8 1 Reference 22 4 Reference
0.23
Any variant 18 21 11.5 (2.1–62.0) 14 32 18.1 (2.0–162.8) 32 53 13.8 (3.6–52.1)
High
wt/wt 6 1 Reference 1 2 Reference 7 3 Reference
Any variant 14 15 6.1 (0.6–58.0) 8 16 2.8 (0.2–46.8) 22 31 3.4 (0.7–16.3)
Sun exposure
at tumor site4
Chronic
wt/wt
8 1 Reference 2 0 Reference 10 1 Reference
0.23
Any variant 9 17 13.9 (1.5–133.3) 8 13 NA 17 30 17.9 (2.0–157.5)
Intermittent
wt/wt 12 3 Reference 15 3 Reference 27 6 Reference
Any variant 22 19 3.4 (0.8–14.0) 14 35 4.4 (0.9–22.1) 36 54 4.4 (1.6–12.2)
Melanoma
thickness5
(below/above
median)
Below
wt/wt 10 2 Reference 6 2 Reference 16 4 Reference
0.43Any variant 14 8 4.8 (0.7–35.2) 6 21 11.4 (1.5–88.2) 20 29 5.6 (1.6–19.4)
Above
wt/wt 3 2 Reference 1 1 Reference 4 3 Reference
Any variant 10 20 5.4 (0.4–66.9) 10 26 3.3 (0.2–64.6) 20 46 3.4 (0.7–17.3)
Nevus count6
(below/above
median)
Below
wt/wt 8 0 Reference 4 1 Reference 8 0 Reference
0.24
Any variant 13 11 NA 12 27 11.5 (1.1–125.2) 17 12 NA
Above
wt/wt 12 4 Reference 4 1 Reference 20 6 Reference
Any variant 19 25 5.3 (1.3–21.2) 8 20 10.0 (1.0–104.2) 35 71 6.7 (2.5–18.3)
BRAF, v-raf murine sarcoma viral oncogene homolog B1; CI, confidence interval; MCIR, melanocortin-1 receptor; OR, odds ratio; wt, wild type; NA, not
available.
Numbers may vary across the strata due to missing variables.
1Numbers in each stratum are based on the specific values of each population (for example, medians of the same variable can vary between populations).
2Models adjusted by median age; the combined analyses could not be adjusted by population because of small numbers in some categories.
3P-value for interaction of the MC1R–BRAF association and the variable of each stratum.
4Chronically exposed sites: face, scalp, neck, back of hands, lower legs, and forearms; intermittently exposed sites: chest, back, upper legs, and upper arms.
Acral melanomas were excluded.
5In situ melanoma was excluded.
6Population 1, X2mm nevi counted on the entire body and population 2, nevi of any size counted on the back only.
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analysis could be extracted only from a subgroup of tissue
specimens, specifically from 92 cases in population 1 and 85 cases
in population 2. Exon 15 of BRAF (NM_004333) was sequenced as
described (Landi et al., 2006). The characteristics of subjects and
melanomas did not substantially differ between cases with or
without data on BRAF mutation status (Table S5 for population 1 and
Landi et al., 2006 for population 2), and thus selection bias is
unlikely, although cannot be excluded.
Statistical analysis
The association between MC1R variants and BRAF-mutant melano-
mas was explored using logistic regression models in case–case and
case–control analyses adjusted for the matching variables and for
other potential confounders, including pigmentation characteristics
and nevus count. OR and corresponding 95% CI adjusted for age are
reported (other adjustments provided similar results). All P-values
were two-sided. For statistical analysis,MC1R variants were grouped
as ‘‘R’’ (R151C, R160W, and D294H) or ‘‘r’’ variants (any non-R
variant excluding synonymous changes), as described previously
(Landi et al., 2005, 2006). Patients were categorized in four groups
based on MC1R genotype to explore possible differences of MC1R
variants (Beaumont et al., 2007).
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SUPPLEMENTARY MATERIAL
Table S1. Distribution of non-synonymous MC1R variants in melanoma
patients and controls of two Italian populations.
Table S2. Comparison of patient and melanoma characteristics between two
Italian populations.
Table S3. Distribution of BRAF-mutant melanomas by melanoma character-
istics in two Italian populations.
Table S4. Risk of melanoma by MC1R germline variants and melanoma BRAF
mutation status in case–control analysis in population 1.
Table S5. Comparison of demographic and phenotypic characteristics of
subjects and melanoma lesions in cases analyzed and not analyzed for BRAF
mutations in population 1.
Table 3. Risk of melanoma in two combined Italian case–control studies by MC1R germline variants and BRAF
mutation status in melanomas
No. of melanoma cases3 OR for melanoma risk (95% CI)4
MC1R
genotype1
No. of
controls2
All
cases
BRAF
wt
BRAF
mutant All cases
P-value
(all cases)
BRAF
wt
P-value
(BRAF wt)
BRAF
mutant
P-value
(BRAF mutant)
wt/wt 121 36 29 7 Reference Reference Reference
Any variant 214 141 54 87 2.2 (1.4–3.4) 0.0003 1.0 (0.6–1.6) 0.94 7.5 (3.3–16.8) o0.0001
wt/wt 121 36 29 7 Reference Reference Reference
r/wt or R/wt 171 95 41 54 1.9 (1.2–2.9) 0.007 1.0 (0.6–1.6) 0.85 5.8 (2.5–13.2) o0.0001
r/r or R/r or R/R 43 46 13 33 3.7 (2.1–6.4) o0.0001 1.1 (0.5–2.4) 0.82 15.3 (6.1–37.6) o0.0001
Total 335 177 83 94 P-trend o0.0001 P-trend 0.91 P-trend o0.0001
wt/wt 121 36 29 7 Reference Reference Reference
r/wt 129 62 27 35 1.6 (1.0–2.7) 0.05 0.8 (0.5–1.5) 0.53 5.1 (2.1–11.9) 0.0002
r/r or R/r or
R/wt or R/R
85 79 27 52 3.1 (1.9–5.0) o0.0001 1.2 (0.7–2.2) 0.54 11.0 (4.8–25.6) o0.0001
Total 335 177 83 94 P-trend o0.0001 P-trend 0.58 P-trend o0.0001
wt/wt 121 36 29 7 Reference Reference Reference
r/wt or r/r 163 77 32 45 1.6 (1.0–2.5) 0.05 0.8 (0.4–1.3) 0.34 5.1 (2.2–11.8) 0.0001
R/wt or R/r or R/R 51 64 22 42 4.2 (2.5–7.2) o0.0001 1.8 (0.9–3.5) 0.09 14.1 (6.1–34.5) o0.0001
Total 335 177 83 94 P-trend o0.0001 P-trend 0.19 P-trend o0.0001
BRAF, v-raf murine sarcoma viral oncogene homolog B1; CI, confidence interval; MCIR, melanocortin-1 receptor; OR, odds ratio; wt, wild type.
1MC1R variants were grouped as ‘‘R’’ (R151C, R160W, and D294H) or ‘‘r’’ variants (any non-R variant excluding synonymous changes) (Landi et al., 2005,
2006).
2One control had missing age and was excluded from the analysis.
3All cases analyzed for BRAF.
4Logistic regression models adjusted by age (quartiles) and population.
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